<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116125</url>
  </required_header>
  <id_info>
    <org_study_id>2019-09-023</org_study_id>
    <nct_id>NCT04116125</nct_id>
  </id_info>
  <brief_title>Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial</brief_title>
  <acronym>OBSERB</acronym>
  <official_title>A Randomized Trial of Sentinel Lymph Node Biopsy vs Radiotherapy Alone After Neoadjuvant Chemotherapy in Patients Undergoing Breast Conserving Surgery With cT1-3N1, ycN0 Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Chilgok Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyungpook National University Chilgok Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OBSERB study is a multi-center, non-blinded, pragmatic, parallel, randomized controlled
      trial in which patients with cT1-3N1 and ycN0 breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OBSERB study aims to compare the oncologic outcomes of radiotherapy without sentinel
      lymph node biopsy versus sentinel lymph node biopsy for the management of breast cancer which
      showed the cN1 was conversed as ycN0 after neoadjuvant chemotherapy.

      To verify whether, the radiotherapy without SLN can be applied, when the cN1 was conversed as
      ycN0 after neoadjuvant chemotherapy.

      To verify whether, the additional treatment decision can be established based on only the
      biology of primary tumor without the pathologic information of axillary lymph nodes To verify
      whether, the patients' quality of life can be improved by a less invasive surgical procedure,
      when the cN1 was conversed as ycN0 after neoadjuvant chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease free survival including breast, axilla and other organs from medical record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Ipsilateral breast from medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axillary recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Ipsilateral axillary lymph nodes from medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Other organs except ipsilateral breast and axillary lymph nodes from medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant free survival</measure>
    <time_frame>5 years</time_frame>
    <description>No disease on other organs except ipsilateral breast and axillary lymph nodes from medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival from medical record</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life by questionnaire</measure>
    <time_frame>5 years</time_frame>
    <description>Pain, Discomfort, Numbness, Rotation of arm, Lymphedema of arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1380</enrollment>
  <condition>Breast Neoplasm Female</condition>
  <condition>Lymphatic Metastasis</condition>
  <arm_group>
    <arm_group_label>Sentinel lymph node biopsy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perform conventional sentinel lymph biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant radiation without Sentinel lymph node biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perform radiotherapy instead of sentinel lymph node biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Adjuvant radiotherapy on axillary region</description>
    <arm_group_label>Adjuvant radiation without Sentinel lymph node biopsy</arm_group_label>
    <arm_group_label>Sentinel lymph node biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women aged &gt; 20 years

          2. cT1-3N1M0, primary invasive

          3. initially confirmed ALN by fine needle aspiration cytology before neoadjuvant
             chemotherapy

          4. completion of neoadjuvant chemotherapy

          5. tumors negative for LN metastasis confirmed by imaging after neoadjuvant chemotherapy

        Exclusion Criteria:

          1. synchronous distant metastases

          2. previous other malignancy

          3. bilateral breast cancer

          4. previous primary systemic therapy

          5. pregnancy or breastfeeding

          6. pre-operative radiological evidence of multiple involved or suspicious axillary nodes

          7. patient with psychiatric, addictive, or any disorder, which compromises ability to
             give informed consent for participation in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Chilgok Hospital</investigator_affiliation>
    <investigator_full_name>JeeYeon Lee</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>cN1, ycN0</keyword>
  <keyword>Neoadjuvant cheotherapy</keyword>
  <keyword>Sentinel Lymph Node</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

